Literature DB >> 33597379

[A Curatively Resected Case of Quadruple Cancer including Synchronous Gastric and Superficial Esophageal Cancers with Metachronous Sigmoid Colon Cancer and Hepatocellular Carcinoma].

Yuko Fukumoto1, Yutaka Takeda, Yoshiaki Ohmura, Yoshiteru Katsura, Takuya Sakamoto, Go Shinke, Kenji Kawai, Tomohiro Kitahara, Masayuki Hiraki, Kohei Murakami, Toru Masuzawa, Atsushi Takeno, Yoshinori Kagawa, Taishi Hata, Kohei Murata.   

Abstract

A 80s year old man was referred to our hospital with melena. Colonoscopy revealed an elevated lesion in the sigmoid colon. Laparoscopic sigmoidectomy(D2)was performed in August 2011. Postoperative diagnosis was advanced sigmoid colon cancer(pT2N1M0 and pStage Ⅲa, UICC). In January 2015, He suffered from epigastric discomfort after meals. Gastrointestinal endoscopy revealed advanced gastric cancer and superficial esophageal cancer. For esophageal cancer, endoscopic submucosal dissection was performed with a diagnosis of cStage 0-Ⅱa(UICC). Laparoscopic distal gastrectomy with Billroth Ⅰ reconstruction was performed for gastric cancer with a diagnosis of pT1bN0M0 and pStage ⅠA(UICC). Follow up CT and MRI images in October 2016 showed a liver tumor in S4/S5. Laparoscopic partial liver resection was performed. Postoperative pathological diagnosis was hepatocellular carcinoma pT1N0M0, pStage Ⅰ(UICC). We finished following up period of the sigmoid colon cancer. Gastric cancer and esophageal cancer are followed up by gastrointestinal endoscopy once a year. Hepatocellular carcinoma is followed up every 3 months. He has no recurrence until now.

Entities:  

Year:  2021        PMID: 33597379

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  The Diagnosis of Early Gastric Cancer Based on Medical Imaging Technology and Mathematical Modeling.

Authors:  Jingying Xiu; Lie Ma; Yanping Ding; Yang Li; Lili Kan; Shi Feng; Fei Wu; Shanshan Xu; Xinan Lu; Ting He; Zhihai Han
Journal:  Comput Math Methods Med       Date:  2022-10-03       Impact factor: 2.809

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.